Sigma Planning Corp’s Neurocrine Biosciences NBIX Stock Holding History

Sigma Planning Corp’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10,008	Closed	-$1.69M	–	1402
2026 Q2	$1.69M	Buy	+10,008	New	+$1.48M	0.04%	414
2024 Q4	–	Sell	-2,000	Closed	-$230K	–	1226
2024 Q3	$230K	Buy	+2,000	New	+$274K	0.01%	1074
2024 Q2	–	Sell	-10,100	Closed	-$1.39M	–	1237
2024 Q1	$1.39M	Buy	+10,100	New	+$1.38M	0.04%	403
2020 Q3	–	Sell	-3,795	Closed	-$463K	–	1131
2020 Q2	$463K	Buy	+3,795	New	+$419K	0.02%	622
2018 Q4	–	Sell	-2,370	Closed	-$291K	–	929
2018 Q3	$291K	Hold	2,370	–	–	0.02%	708
2018 Q2	$233K	Sell	2,370 -1,020	-30%	-$91.3K	0.02%	764
2018 Q1	$281K	Buy	3,390 +290	+9%	+$24.5K	0.02%	633
2017 Q4	$241K	Buy	+3,100	New	+$211K	0.02%	695

Other funds holding NBIX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sigma Planning Corp's NBIX Position: Q3 2026 in Review

Sigma Planning Corp sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 10,008 shares — an estimated $1.69M sold.

Sigma Planning Corp first reported a position in NBIX in Q4 2017 and held it in 8 quarters. The position peaked at $1.69M in Q2 2026. 365 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Sigma Planning Corp reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
Sigma Planning Corp sold 10,008 Neurocrine Biosciences shares in Q3 2026, an estimated $1.69M.
Sigma Planning Corp first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 8 quarters.
Sigma Planning Corp's Neurocrine Biosciences position peaked at $1.69M in Q2 2026.
365 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.